Protein / target

Glucagon-like peptide 2 receptor

GLP2RO95838
UniProt: O95838
13
Research papers

Protein at a glance

Research activity

Emerging research

13 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Research activity

13 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.1,702 cites

Pfeffer MA · The New England journal of medicine · 2015

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.78 cites

Regmi A · Cell metabolism · 2024

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.62 cites

Chuang MH · JAMA network open · 2024

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.53 cites

Jalleh RJ · The Journal of clinical endocrinology and metabolism · 2024

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.50 cites

Tobaiqy M · International journal of clinical pharmacy · 2024

Recent

Targeting the GLP-2 receptor in the management of obesity.

Pálsson TG · Peptides · 2024

Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.

Regmi A · Cell metabolism · 2024

Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.

Dubin RL · Diabetes, obesity & metabolism · 2024

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.

Jalleh RJ · The Journal of clinical endocrinology and metabolism · 2024

GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.

Singh A · World journal of gastroenterology · 2024

Lead-in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice.

Petersen J · Molecular metabolism · 2024

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.

Stefanou MI · European stroke journal · 2024

Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.

Caruso I · Endocrine · 2024

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.

Chuang MH · JAMA network open · 2024

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.

Tobaiqy M · International journal of clinical pharmacy · 2024

Europe PMC papers linked directly to this protein.